Literature DB >> 26176332

Osteopontin is proteolytically processed by matrix metalloproteinase 9.

Merry L Lindsey1,2,3, Fouad A Zouein1,2, Yuan Tian1,2, Rugmani Padmanabhan Iyer1,2, Lisandra E de Castro Brás1,4.   

Abstract

Osteopontin is robustly upregulated following myocardial infarction (MI), which suggests that it has an important role in post-MI remodeling of the left ventricle (LV). Osteopontin deletion results in increased LV dilation and worsened cardiac function. Thus, osteopontin exerts protective effects post-MI, but the mechanisms have yet to be defined. Matrix metalloproteinases (MMPs) regulate LV remodeling post-MI, and osteopontin is a known substrate for MMP-2, -3, -7, and -9, although the cleavage sites have not been mapped. Osteopontin-derived peptides can exert distinct biological functions that may depend on their cleavage sites. We mapped the MMP-9 cleavage sites via LC-MS/MS analysis using label-free and N-terminal labeling methods, and compared them with those of MMP-2, -3, and -7. Each MMP yielded a unique cleavage profile with few overlapping cleavage sites. Using synthetic peptides, we validated 3 sites for MMP-9 cleavage at amino acid positions 151-152, 193-194, and 195-196. Four peptides were synthesized based on the upstream- and downstream-generated fragments and were tested for biological activity in isolated cardiac fibroblasts. Two peptides increased cardiac fibroblast migration rates post-wounding (p < 0.05 compared with the negative control). Our study highlights the importance of osteopontin processing, and confirms that different cleavage sites generate osteopontin peptides with distinct biological functions.

Entities:  

Keywords:  MMP-9; MPM-9; cardiac; cardiaque; cleavage sites; fibroblastes; fibroblasts; infarctus du myocarde; mass spectrometry; matrix metalloproteinases; myocardial infarction; métalloprotéinases matricielles; osteopontin; ostéopontine; peptides; proteomics; protéomique; sites de clivage; spectométrie de masse

Mesh:

Substances:

Year:  2015        PMID: 26176332      PMCID: PMC4764993          DOI: 10.1139/cjpp-2015-0019

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  30 in total

Review 1.  Osteopontin.

Authors:  J Sodek; B Ganss; M D McKee
Journal:  Crit Rev Oral Biol Med       Date:  2000

2.  Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome.

Authors:  Richard A Dean; Christopher M Overall
Journal:  Mol Cell Proteomics       Date:  2007-01-01       Impact factor: 5.911

Review 3.  Matricellular proteins: new molecular targets to prevent heart failure.

Authors:  Hiroshi Okamoto; Kyoko Imanaka-Yoshida
Journal:  Cardiovasc Ther       Date:  2011-08-04       Impact factor: 3.023

Review 4.  Osteopontin - a multi-modal marker and mediator in atherosclerotic vascular disease.

Authors:  Talya Wolak
Journal:  Atherosclerosis       Date:  2014-07-29       Impact factor: 5.162

5.  Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2014-01-21       Impact factor: 29.690

6.  Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin.

Authors:  N A Trueblood; Z Xie; C Communal; F Sam; S Ngoy; L Liaw; A W Jenkins; J Wang; D B Sawyer; O H Bing; C S Apstein; W S Colucci; K Singh
Journal:  Circ Res       Date:  2001-05-25       Impact factor: 17.367

7.  Distribution of SPARC during neovascularisation of degenerative aortic stenosis.

Authors:  A Charest; A Pépin; R Shetty; C Côté; P Voisine; F Dagenais; P Pibarot; P Mathieu
Journal:  Heart       Date:  2006-05-18       Impact factor: 5.994

Review 8.  Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates.

Authors:  Rugmani Padmanabhan Iyer; Lisandra E de Castro Brás; Yu-Fang Jin; Merry L Lindsey
Journal:  Circ Res       Date:  2014-02-28       Impact factor: 17.367

9.  Extracellular matrix remodeling in canine and mouse myocardial infarcts.

Authors:  M Dobaczewski; M Bujak; P Zymek; G Ren; M L Entman; N G Frangogiannis
Journal:  Cell Tissue Res       Date:  2006-02-22       Impact factor: 5.249

10.  Matrix metalloproteinase-9 (MMP-9) and myeloperoxidase (MPO) levels in patients with nonobstructive coronary artery disease detected by coronary computed tomographic angiography.

Authors:  Zhi-Hui Hou; Bin Lu; Yang Gao; Hui-Li Cao; Fang-Fang Yu; Na Jing; Xi Chen; Xiang-Feng Cong; Sion K Roy; Matthew J Budoff
Journal:  Acad Radiol       Date:  2012-09-02       Impact factor: 3.173

View more
  25 in total

1.  Regulation of Cellular Redox Signaling by Matricellular Proteins in Vascular Biology, Immunology, and Cancer.

Authors:  David D Roberts; Sukhbir Kaur; Jeffrey S Isenberg
Journal:  Antioxid Redox Signal       Date:  2017-09-08       Impact factor: 8.401

Review 2.  Proteomic analysis of the cardiac extracellular matrix: clinical research applications.

Authors:  Merry L Lindsey; Mira Jung; Michael E Hall; Kristine Y DeLeon-Pennell
Journal:  Expert Rev Proteomics       Date:  2018-01-09       Impact factor: 3.940

3.  Matrix Metalloproteinase 9 and Osteopontin Interact to Support Synaptogenesis in the Olfactory Bulb after Mild Traumatic Brain Injury.

Authors:  Melissa A Powell; Raiford T Black; Terry L Smith; Thomas M Reeves; Linda L Phillips
Journal:  J Neurotrauma       Date:  2019-01-10       Impact factor: 5.269

Review 4.  Matrix Metalloproteinases in Myocardial Infarction and Heart Failure.

Authors:  Kristine Y DeLeon-Pennell; Cesar A Meschiari; Mira Jung; Merry L Lindsey
Journal:  Prog Mol Biol Transl Sci       Date:  2017-03-18       Impact factor: 3.622

Review 5.  Assigning matrix metalloproteinase roles in ischaemic cardiac remodelling.

Authors:  Merry L Lindsey
Journal:  Nat Rev Cardiol       Date:  2018-08       Impact factor: 32.419

Review 6.  Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension.

Authors:  Thenappan Thenappan; Stephen Y Chan; E Kenneth Weir
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-24       Impact factor: 4.733

Review 7.  Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.

Authors:  Hiroe Toba; Merry L Lindsey
Journal:  Pharmacol Ther       Date:  2018-08-25       Impact factor: 12.310

Review 8.  Understanding cardiac extracellular matrix remodeling to develop biomarkers of myocardial infarction outcomes.

Authors:  Signe Holm Nielsen; Alan J Mouton; Kristine Y DeLeon-Pennell; Federica Genovese; Morten Karsdal; Merry L Lindsey
Journal:  Matrix Biol       Date:  2017-12-14       Impact factor: 11.583

9.  Mechanical regulation of cardiac fibroblast profibrotic phenotypes.

Authors:  Kate M Herum; Jonas Choppe; Aditya Kumar; Adam J Engler; Andrew D McCulloch
Journal:  Mol Biol Cell       Date:  2017-05-03       Impact factor: 4.138

10.  Roles of osteopontin and matrix metalloproteinase-7 in occurrence, progression, and prognosis of nonsmall cell lung cancer.

Authors:  Ying Sun; Dan Li; Xiao-Hong Lv; Shu-Cheng Hua; Ji-Chang Han; Feng Xu; Xian-Dong Li
Journal:  J Res Med Sci       Date:  2015-12       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.